ATCC's High Containment Facility Renovations in Support of NIAID and Pandemic Preparedness

ATCC 的高密闭设施改造支持 NIAID 和流行病防范

基本信息

批准号：
10611743
负责人：
Rebecca Bradford
金额：
$ 386.27万
依托单位：
AMERICAN TYPE CULTURE COLLECTION
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-16 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10611743
关键词：
2019-nCoV 3-Dimensional Air Conditioning Alphavirus American Type Culture Collection Animals Antiviral Agents Basic Science Biological Assay COVID-19 Categories Collaborations Communicable Diseases Communities Computer Security Containment Coronavirus Country Data Decontamination Development Diagnostic Dimensions Disease Outbreaks Doctor of Philosophy Ebola Ebola virus Emerging Communicable Diseases Equipment FDA approved Family Fostering Foundations Funding Goals Health Heating Human Infection Infectious Agent Infectious Diseases Research Influenza A Virus, H1N1 Subtype Institution Laboratories Logistics Longevity Microbiology Middle East Respiratory Syndrome Mission Modernization National Institute of Allergy and Infectious Disease Orthobunyavirus Pathogenesis Peptides Pharmaceutical Preparations Production Protocols documentation Publications RNA RNA Viruses Readiness Reagent Regulation Research Research Personnel Research Support Resource Sharing Resources Scientist Services Ships System Therapeutic Translating Translational Research Vaccines Viral Virginia Virus ZIKA Zika Virus antimicrobial base biobank biocontainment facility biodefense emerging pathogen facility renovation human pathogen in vitro Model influenzavirus novel pandemic disease pandemic preparedness pathogen pre-clinical priority pathogen product development programs repaired response response biomarker screening small molecule square foot tool two-dimensional ventilation working group

项目摘要

Project Summary: The proposed project aims to renovate ATCC's High Containment Facility (HCF) at the American Type Culture Collection (ATCC) in Manassas, Virginia. ATCC's 7,500 ft2 biocontainment facility was built in 2007 with funding from NIAID and has been dedicated to developing infectious disease strains and reagents needed to rapidly advance diagnostics, vaccines, and therapeutics against priority pathogens. Since 2003, ATCC has partnered with NIAID to centralize and provide critical scientific resources through the Biodefense and Emerging Infections Resources (BEI Resources) program. The NIAID established BEI Resources to provide the global research community with reagents, tools, and information for studying Category A, B, and C priority pathogens, emerging infectious disease agents, and other microbiological materials relevant to human health. Over the past 18 years, ATCC has provided over 1,360,000 reagents to over 14,000 investigators at 3,740 institutions in 119 countries spanning over 500 human pathogens in NIAID's priority portfolio. During this period, BEI Resources has provided critical materials for vital disease outbreaks, including H1N1, MERS, Ebola, and Zika. Over the past two years, ATCC has rapidly created more than 690 SARS-CoV-2 products; acquired, produced, and authenticated more than 165 stocks of SARS-CoV-2 for both general research and challenge studies; and shipped more than 86,000 research reagents to over 2,800 researchers in more than 70 countries for the development of countermeasures and basic research. The material provided by BEI Resources has been cited in more than 1,800 SARS-CoV-2 publications since February of 2020. In addition, ATCC has fostered collaboration and partnerships across NIAID programs and external working groups to share resources, information, and data to accelerate discoveries and harmonize scientific approaches for pandemic response and preparedness. ATCC's high containment facility houses laboratories essential for BSL-3 and Select Agent infectious disease research, product development, and large-scale reagent production for the research community. This proposal aims to renovate and upgrade the HVAC, decontamination, and security systems. The renovations also include upgrades to fixed equipment and interior finishing in the facility. The renovations will modernize the facility for use by 40 Ph.D. ATCC scientists, collaborators, and laboratory support staff. The products and services developed in the facility will support thousands of scientists globally each year to prepare and respond to pandemics. ATCC is seeking this opportunity for engagement with the NIAID to invest in this facility which has been foundational for the nation's pandemic response and preparedness.

项目摘要：拟议的项目旨在翻新美国ATCC的高遏制设施（HCF）弗吉尼亚州马纳萨斯的类型文化收藏（ATCC）。 ATCC的7,500 FT2生物内在设施建于2007年，由NIAID提供资金，一直致力于发展感染性疾病菌株和试剂需要快速提高诊断，疫苗和疗法针对优先病原体。自2003年以来，ATCC与NIAID合作以集中化并提供通过生物幻影和新兴感染资源（BEI）进行关键的科学资源（BEI）资源）程序。 NIAID建立的BEI资源以提供全球研究具有试剂，工具和信息的社区，用于研究A类，B和C优先级病原体，新兴的传染病药物和其他与人类健康。在过去的18年中，ATCC为超过1,360,000种试剂提供了 119个国家 /地区的3,740个机构的14,000名调查员跨越了500多个人类病原体在Niaid的优先投资组合中。在此期间，BEI资源为包括H1N1，MERS，Ebola和Zika在内的重要疾病暴发。在过去的两年中，ATCC 迅速创建了超过690个SARS-COV-2产品；获得，生产和身份验证一般研究和挑战研究都有165多种SARS-COV-2股票；和在70多个国家 /地区的2800多个研究人员中运送了86,000多种研究试剂为了发展对策和基础研究。 Bei提供的材料自2020年2月以来，已经在1,800多个SARS-COV-2出版物中引用了资源。此外，ATCC还建立了NIAID计划的协作和合作伙伴关系，外部工作组共享资源，信息和数据以加速发现和协调科学方法的大流行反应和准备。 ATCC的高遏制设施设有BSL-3必不可少的实验室和精选代理传染病研究，产品开发和大规模试剂生产研究社区。该建议旨在翻新和升级HVAC，净化，和安全系统。翻新工程还包括对固定设备和内部的升级在设施中完成。翻新工程将使该设施现代化40博士学位。 ATCC 科学家，合作者和实验室支持人员。产品和服务在设施将每年在全球数千名科学家准备并做出回应大流行。 ATCC正在寻求与NIAID参与投资的机会该设施是该国大流行反应和准备的基础。